RE:RE:SilenceThe phase II clinical trial process averages 3.6 years from planning-execution-data. I am from the school of thought that no news is good news and when material items happen they will be announced. Given the discussed AKI trial is not a COVID trial, new drug would have to be manufactured/trial design completed and applications made to regulators. This is the unsexy part of the biosciences sector, but when the cycle begins I look forward to the share structure and the supply/demand that will take place in the markets. When you want to be taken seriously by the markets as a company working towards commercializing you have to act the part, I am unsure how managements wallets are going to create material news as mentioned in the previous post but the ceo as the largest shareholder gives me confidence in shareholder value.